The FDA approved UroGen Pharma’s (NASDAQ:URGN) mitomycin gel for the treatment of low-grade upper tract urothelial cancer (UTUC). The gel, which will be marketed under the brand name Jelmyto, inhibits DNA transcription...
UroGen Pharma (NASDAQ:URGN) reported results from its Phase 3 and Phase 2b trials of its mitomycin gel in patients with low-grade upper tract urothelial cancer (UTUC) and intermediate risk low-grade non-muscle invasive...